Pulmonary-Allergy Drugs Advisory Committee
Committee Meeting on March 8, 2011, from 8 a.m. to 5 p.m.
Agenda: On March 8, 2011, the committee will discuss new drug application (NDA) 022-383, indacaterol maleate (ARCAPTA NEOHALER), by Novartis Pharmaceuticals Corp., for the long-term once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment